Catalona, W., & Maggiore, J. (2005). PSA and free-PSA testing for prostate cancer is still a life saver. Clinical Lab Products. http://www.clpmag.com/2005/02/psa-and-free-psa-testing-for-prostate-cancer-is-still-a-lifesaver/".Goonetilleke, K., & Siriwardena, A. (2007). Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 33(3):266–70.
Keshaviah, A., Dellapasqua, A., & Rotmensz, A. (2007). CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven international breast cancer study group trials. Annals of Oncology. 18:701–708.
Lin, K., & Barton, M. (2012). Screening for ovarian cancer - evidence update for the U.S. preventive services task force reaffirmation recommendation statement. United States Preventive Services Task Force.
Rack, B., Schindbeck, C., & Jϋckstock J. (2010). Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment. Anticancer Res. 30(5):1837-1841.
Stamey, T., Caldwell, M., McNeal, J., & Nolley, R., et al. (2004). The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urology. 172:1297-1301.
Sturgeon, C. (2019). Tumor Markers. Tietz fundamentals of clinical chemistry and molecular diagnostics. (8th ed., pp. 717-760). Elsevier.
The role of the obstetrician–gynecologist in the early detection of epithelial ovarian cancer. (2011). Obstetrics & Gynecology. 117(3):742–746.
Thompson, I., Pauler, D., Goodman, P., & Tangen, C., et al. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng per milliliter. N Engl J Med. 350:2239-2246.
Verring, A., Clouth, A., Ziolowski, P., & Oremek, G. (2011). Clinical usefulness of cancer markers in primary breast cancer. ISRN Pathology. doi:10.5402/2011/817618.
